- Home
- XNCR vs KROS Comparison
XNCR vs KROS Comparison
Compare XNCR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- KROS
- Stock Information
- Founded
- XNCR 1997
- KROS 2015
- Country
- XNCR United States
- KROS United States
- Employees
- XNCR N/A
- KROS N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- XNCR Health Care
- KROS Health Care
- Exchange
- XNCR Nasdaq
- KROS Nasdaq
- Market Cap
- XNCR 1.7B
- KROS 1.8B
- IPO Year
- XNCR 2013
- KROS 2020
- Fundamental
- Price
- XNCR $24.20
- KROS $17.03
- Analyst Decision
- XNCR Strong Buy
- KROS Buy
- Analyst Count
- XNCR 9
- KROS 11
- Target Price
- XNCR $36.33
- KROS $78.33
- AVG Volume (30 Days)
- XNCR 850.2K
- KROS 1.8M
- Earning Date
- XNCR 11-06-2024
- KROS 11-06-2024
- Dividend Yield
- XNCR N/A
- KROS N/A
- EPS Growth
- XNCR N/A
- KROS N/A
- EPS
- XNCR N/A
- KROS N/A
- Revenue
- XNCR $85,164,000.00
- KROS $651,000.00
- Revenue This Year
- XNCR N/A
- KROS $224.66
- Revenue Next Year
- XNCR $89.22
- KROS N/A
- P/E Ratio
- XNCR N/A
- KROS N/A
- Revenue Growth
- XNCR N/A
- KROS 8037.50
- 52 Week Low
- XNCR $15.31
- KROS $15.67
- 52 Week High
- XNCR $27.24
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- XNCR 44.92
- KROS 22.60
- Support Level
- XNCR $22.74
- KROS $16.31
- Resistance Level
- XNCR $25.54
- KROS $21.05
- Average True Range (ATR)
- XNCR 1.17
- KROS 3.29
- MACD
- XNCR -0.33
- KROS -4.56
- Stochastic Oscillator
- XNCR 22.00
- KROS 2.40
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.